scholarly journals The anticancer mechanism of human antimicrobial peptide LL-37

2021 ◽  
pp. 261-268
Author(s):  
Aqeel Ahmad ◽  
Mohammed Ali Mullah Fawaz
Keyword(s):  
Gastric Cancer ◽  
Colon Cancer ◽  
Squamous Cell Carcinoma ◽  
Antimicrobial Peptide ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Hematologic Malignancy ◽  
Gastric Cancer Cells ◽  
Medicinal Uses ◽  
Anticancer Mechanism

Human antimicrobial peptides LL-37 have a variety of medicinal uses. It has been portrayed that this peptide has robust tumoricidal action in a range of malignancies, particularly ovarian cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, malignant melanoma, and squamous cell carcinoma of the skin. It exhibits substantial anticancer action against a range of cancers, including colon cancer, gastric cancer, hematologic malignancy, and oral squamous cell carcinoma (OSCC), in comparison. In this review, we explored in depth the anticancer mechanism of action of LL-37 in numerous sorts of cancer. We have shown how LL-37 impedes colon cancer by eliciting caspase-independent apoptosis. LL-37, in addition, has been noticed to boost tumor-suppressive bone morphogenetic protein signaling in gastric cancer cells via restricting the proteasome, which has been previously reported. In this research, we investigated how DNA methylation interferes with the activity of the human CAMP (Cathelicidin antimicrobial peptide gene) promoter and, as a result, acts as a tumor inhibitor in mouth squamous cell carcinoma. Additionally, how LL-37 inhibits cancer cell development in hematologic malignancy has been explored through caspase-independent but Ca2+/calpain- and AIF-dependent processes.

scholarly journals Adenosquamous Carcinoma of the Colon

2018 ◽  
Vol 11 (3) ◽  
pp. 791-796 ◽  
Author(s):  
Tagore Sunkara ◽  
Megan E Caughey ◽  
Priyanka Makkar ◽  
Febin John ◽  
Vinaya Gaduputi
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Adenosquamous Carcinoma ◽  
Colorectal Cancers ◽  
Men And Women ◽  
Carcinoma Of The Colon ◽  
The Third

Overall, colorectal cancer is the third most commonly diagnosed cancer in both men and women, meaning that it is one of the more widely recognized preventable cancers. Instances of colorectal malignancies though are overwhelmingly attributable to adenocarcinoma. Colorectal cancers with components of squamous cell carcinoma represent a statistical anomaly. Here, we present the case of a 50-year-old male, who complained of abdominal pain and weight loss over a 3-month period of time. Biopsies from a colonoscopy ultimately revealed that this patient’s colon cancer consisted of both adenocarcinoma and squamous cell carcinoma, representing a truly exceptional pathology finding in a patient diagnosed with a colorectal cancer.

Primary squamous cell carcinoma of the liver concomitant with primary colon cancer: report of a case

2013 ◽  
Vol 6 (2) ◽  
pp. 134-138 ◽  
Author(s):  
Kiyoto Morito ◽  
Keita Kai ◽  
Atsushi Miyoshi ◽  
Hiroshi Kubo ◽  
Takao Ide ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Primary Squamous Cell Carcinoma ◽  
Primary Colon Cancer ◽  
Primary Colon

Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 68-68 ◽  
Author(s):  
Thomas Benjamin Karasic ◽  
Mark H. O'Hara ◽  
Ursina R. Teitelbaum ◽  
Nevena Damjanov ◽  
Bruce J. Giantonio ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gastric Adenocarcinoma ◽  
Cancer Progression ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Trial ◽  
Single Agent ◽  
Carcinoma Of The Esophagus

68 Background: Dysregulation of the cell cycle is a hallmark of cancer. Progression through the G1/S transition requires phosphorylation of retinoblastoma (RB) by cyclin-dependent kinases 4 and 6 (CDK4/6), which are regulated by cyclins D and E. A positive feedback loop between apoptosis signal-regulating kinase 1 (ASK1), a member of the MAP kinase pathway, and cyclin D1 has been shown to drive cell proliferation in gastric cancer. In addition, amplification of cyclin D loci and/or activating mutations in CDKs are frequent molecular aberrations in gastroesophageal malignancies. We hypothesized that palbociclib, a potent inhibitor of CDK4/6 would disrupt proliferative signaling, and arrest the growth of gastric cancer. We conducted a phase II trial of palbociclib in gastric and esophageal cancers as an initial test of efficacy. Methods: We screened 38 subjects with gastric, GE junction, or esophageal cancer for RB nuclear expression by immunohistochemistry, and 38/38 (100%) were positive. We enrolled 21 subjects, of whom 5 had gastric adenocarcinoma, 3 had GE junction adenocarcinoma, 8 had esophageal adenocarcinoma, and 5 had esophageal squamous cell carcinoma. Four of 19 subjects tested positive for CCND1 overexpression by FISH. Patients received 125mg daily of palbociclib for days 1-21 of 28-day cycles. Results: Subjects remained on treatment for a median of 1.7 months. By the initial 2-month assessment, 5 of 21 subjects had stable disease, and 16 subjects had progressive disease by imaging and/or clinical progression. No objective responses were seen. The maximum duration of therapy was 5.5 months in two subjects. One of these subjects had progressing HER2-amplified gastric adenocarcinoma, and continued concurrent trastuzumab with palbociclib, while the other had squamous cell carcinoma of the esophagus. Grade 3 or 4 cytopenias occurred in 9 of 21 subjects (43%), with neutropenia in 8 (38%), anemia in 4 (19%), and thrombocytopenia in 1 (5%). One subject discontinued therapy due to grade 4 thrombocytopenia with GI bleed. All other subjects discontinued therapy due to disease progression. Conclusions: Palbociclib has modest single-agent activity in gastroesophageal tumors despite universal RB expression. Clinical trial information: NCT01037790.

scholarly journals A case of pernicious anemia associated with early gastric cancer (Type IIa+IIc) and squamous cell carcinoma of the oral mucosa.

1989 ◽  
Vol 78 (10) ◽  
pp. 1482-1483
Author(s):  
Eiji KAWASAKI ◽  
Hirohumi TAKINO ◽  
Ryuji FURUKAWA ◽  
Hisao TAGUCHI ◽  
Masuko TAGAWA ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Squamous Cell Carcinoma ◽  
Early Gastric Cancer ◽  
Pernicious Anemia ◽  
Cell Carcinoma ◽  
Oral Mucosa ◽  
Squamous Cell ◽  
Cancer Type

scholarly journals Mixed Neuroendocrine Carcinoma and Squamous Cell Carcinoma of the Colon: Case Report and Literature Review

2018 ◽  
Vol 12 (2) ◽  
pp. 240-246 ◽  
Author(s):  
Shinya Munakata ◽  
Yuta Murai ◽  
Akihiro Koizumi ◽  
Hisaki Kato ◽  
Riku Yamamoto ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Squamous Cell ◽  
Lung Metastases ◽  
Carcinoma Of The Colon ◽  
Additional Chemotherapy ◽  
Old Japanese ◽  
Descending Colon Cancer

Neuroendocrine carcinoma (NEC) of the colon is very rare, and squamous cell carcinoma (SCC) of colon cancer is rare. We recently treated a patient with both NEC and SCC that initially presented as multiple unresectable liver and lung metastases. A 68-year-old Japanese man was referred to our hospital because of diarrhea with descending colon cancer obstruction. He underwent a left colectomy. Based on immunohistochemistry results, we diagnosed mixed NEC and SCC, the primary lesion location of which was probably the lung in the final pathologic examination. He began systemic palliative chemotherapy with CDDP and CPT-11. After 3 months of treatment, shown the progressive disease, we started CDDP and VP-16. The patient was not eligible for additional chemotherapy after 2 months.

Sign in / Sign up

Export Citation Format

Share Document